Robert Williamson, an experienced biotech executive with an impressive track record for building successful companies, is seeking new opportunities on the West Coast. With expertise in financing, non-dilutive partnerships, business development, M&A, public and private boards, and investor relations, Williamson has led the growth, IPO, financing, commercial ramp-up and sale of numerous biotech companies. Notably, his leadership was instrumental in the successful sale of Pharmasset to Gilead for $11B.

Williamson studied for an MBA at Stanford University Graduate School of Business and holds a BA from Pomona College. He is the owner of LaSalle Venture Advisers and has held executive positions and board memberships at companies including Rickshaw Therapeutics, Aegle Therapeutics, Naia Limited, Arriva Pharmaceuticals, Eos Biotechnology, and BrainCells, Inc. Williamson has also served as the committee chair and director at Progen Pharmaceuticals Limited and Pharmasset, Inc., and has been a consultant and adviser to BioVerdant, HX Diagnostics, Inc., Nodality, Inc., and DoubleTwist, Inc.

With a focus on building companies through partnerships, private funding, and public capital markets, Williamson is adept at communicating complex financial and strategic concepts. He is a former committee chairman and has significant public board and committee chairman experience. Williamson is seeking C-level opportunities that can leverage his expertise and can be reached at RobW@LaSalleAdvisers.com.